Latest News

Jan 12, 2021: HEALEY ALS Platform Trial Offers Study Drug Webinar Series
A new webinar series gives members of the ALS community the opportunity to learn about the mechanism of action and science behind each of the 4 drugs currently being tested in the Platform Trial. Attendees will be able to interact with the researchers who developed these drugs and submit questions live.
Read Announcement.

Jan 8, 2021: Trial Participants Begin Receiving Investigational Drug Pridopidine
Investigators have now added a fourth promising drug—pridopidine—to the HEALEY ALS Platform Trial, and the first participant has received the study drug at the Mass General Hospital site.
Read Announcement.

Dec 18, 2020: I AM ALS Grant for New EAP
Thanks to a grant from I AM ALS, a treatment from the HEALEY ALS Platform Trial will be made available to additional patients outside the trial.
Read Announcement.

Dec 15, 2020: Investigational Drug SLS-005 (Trehalose) Approved for HEALEY ALS Platform Trial
Investigators are now working with Seelos to include SLS-005 (Trehalose) in the trial.
Read Announcement.

All Healey Center News

Patient & Community Webinar Series

We are committed to an ongoing dialogue about the HEALEY ALS Platform Trial with the entire ALS patient community.

We will continue to share enrollment updates as well as new ideas and opportunities. Our team will be available to answer all questions that the community might have about this groundbreaking trial.

In addition to occasional comprehensive updates, we host weekly informal Q&A sessions. The idea of weekly interactive sessions came from our Patient Advisory Committee and we absolutely love the opportunity to connect with all who might be interested on a frequent basis. Please join us as often as you would like!

To submit questions prior to the webinars please email healeyalsplatform@mgh.harvard.edu

Upcoming Webinars

Previous Webinars

January 21: Weekly Q&A
Research scientists from the Prilenia Therapeutics presented the rationale and science behind their Priodipidine, one of the investigational treatments being tested in the HEALEY ALS Platform Trial.
Recording and slides available soon.

January 14: Weekly Q&A
Sabrina Paganoni, MD, PhD and Merit Cudkowicz, MD, MSc presented the week's updates on the HEALEY ALS Platform Trial, discussed the expanded access program, and answered questions from the audience.
Watch recording | Download slides (PDF)

Previous Webinars

January 7: Weekly Q&A
Sabrina Paganoni, MD, PhD and Merit Cudkowicz, MD, MSc presented the week's updates on the HEALEY ALS Platform Trial, discussed the expanded access program, and answered questions from the audience.
Watch recording | Download slides (PDF)

December 17: Weekly Q&A
Sabrina Paganoni, MD, PhD and Merit Cudkowicz, MD, MSc presented the week’s updates on the HEALEY ALS Platform Trial, discussed open label extension and COVID impact, and answered questions from the audience.
Watch recording | Download slides (PDF)

December 10: Weekly Q&A
Sabrina Paganoni, MD, PhD presented this week's updates on the HEALEY ALS Platform Trial, discussed the enrollment process and study visits, and answered questions from the audience.
Watch recording | Download slides (PDF)

December 3: Weekly Q&A
Sabrina Paganoni, MD, PhD and Merit Cudkowicz, MD, MSc presented the week's updates on the HEALEY ALS Platform Trial and the Expanded Access Program, discussed the relationship between clinical research trials for ALS and clinical care, and answered questions from the audience.
Watch recording | Download slides (PDF)

November 30: Monthly Update
Merit Cudkowicz, MD, MSc, principal investigator, and Sabrina Paganoni, MD, co-principal investigator of the HEALEY ALS Platform Trial, provided an update on the progress of the HEALEY ALS Platform Trial. They were joined by Jen DiMartino of ALS One.
Watch recording | Download slides (PDF)

November 19: Weekly Q&A
Sabrina Paganoni, MD, PhD presented the week’s updates on the HEALEY ALS Platform Trial and answered questions from the audience.
Watch recording | Download slides (PDF)

November 12: Weekly Q&A
Sabrina Paganoni, MD, PhD and Merit Cudkowicz, MD, MSc presented the week’s updates on the HEALEY ALS Platform Trial and answered questions from the audience.
Watch recording | Download slides (PDF)

November 5: Weekly Q&A
Sabrina Paganoni, MD, PhD presented the week’s updates on the HEALEY ALS Platform Trial and answered questions from the audience.
Watch recording | Download slides (PDF)

October 29: Monthly Update
Merit Cudkowicz, MD, MSc, principal investigator, and Sabrina Paganoni, MD, co-principal investigator of the HEALEY ALS Platform Trial, provided an update on the progress of the HEALEY ALS Platform Trial. They were joined by Troy Green from Tackle ALS and Peter Foss from ALS Finding a Cure.
Watch recording | Download slides (PDF)

October 22: Weekly Q&A
Enrollment updates, trial sites, and patient questions.
Watch recording | Download slides (PDF)

October 21: ALS/MND Alliance Clinical Trial Design Webinar
Merit Cudkowicz, MD, MSc joined researchers from Europe and Scotland to discuss new research and clinical trial models, how they will change the landscape going forward and their practical implications for patients and researchers.
Watch recording

October 15: Weekly Q&A
Sabrina Paganoni, MD, PhD covers newly active trial sites, patient navigator service, and patient questions about the HEALEY ALS Platform Trial.
Watch recording | Download slides (PDF)

October 13: CTTI Master Protocol Development Webinar for Researchers
Marianne Chase, the Senior Director Clinical Trial Operations at Mass General's Neurological Clinical Research Institute, joined representatives from the FDA, Janssen R&D and Edgewise Therapeutics to discuss the design of master protocol clinical trials, which allow researchers to answer multiple scientific questions within a single trial. Watch recording.

October 8: Weekly Q&A
Mass General researchers Merit Cudkowicz, MD, MSc and Sabrina Paganoni, MD, PhD are joined by Sandy Morris of I AM ALS.
Watch recording | Download slides (PDF)

September 29, 2020: Monthly Update
Merit Cudkowicz, MD, MSc, principal investigator, and Sabrina Paganoni, MD, co-principal investigator of the HEALEY ALS Platform Trial, provided an update on the progress of the HEALEY ALS Platform Trial. They were joined by Kuldip Dave, PhD, of the ALS Association.
Watch recording | Download slides (PDF)

August 27, 2020: Monthly Update
Sabrina Paganoni, MD, co-principal investigator of the HEALEY ALS Platform Trial, joined Taner Dagdelen, co-founder and CEO of Unite Genomics, for a webinar on August 27 to discuss the latest updates on the trial.
Watch recording

Watch Our Launch Video

Pre-Launch Update

July 7, 2020: Status Update
Healey Center faculty provide update on the status of the HEALEY ALS Platform Trial.
Watch recording.

March 25, 2020: COVID Updates and April 8th Webinar
As you all are, we too are closely monitoring the impact of COVID-19 on the HEALEY ALS Platform Trial timelines and operations.  The bottom line is this: we are committed to beginning the trial as soon and as safely as we can.

January 22, 2020: Sean M. Healey & AMG Center for ALS at Mass General receives “May Proceed” notice for three drugs in first ALS platform trial
The Sean M. Healey & AMG Center for ALS at Mass General has received approval from the U.S. Food and Drug Administration (FDA) to proceed with administering three proposed drug regimens in the HEALEY ALS Platform Trial – the first trial of its kind for amyotrophic lateral sclerosis (ALS)

Merit Cudkowicz, MD, MSc, Director of the Healey Center for ALS, discusses the impact of the “May Proceed” notice from the FDA for three drugs in first ALS platform trial

January 14, 2020: ALS Association makes multi-year commitment to HEALEY ALS Platform Trial
The ALS Association announced a $3 million commitment to the first platform trial for ALS, taking place at the Sean M. Healey & AMG Center for ALS at Mass General in collaboration with the Barrow Neurological Institute and the Northeast ALS Consortium (NEALS).

September 18, 2019: Sean M. Healey & AMG Center for ALS at Mass General launches first ALS Platform Trial with 5 promising drugs
The Sean M. Healey & AMG Center at Massachusetts General Hospital will launch the first platform trial for amyotrophic lateral sclerosis (ALS) to accelerate the development of effective and breakthrough treatments for people with ALS.